Comparative Pharmacology
Head-to-head clinical analysis: GLEOSTINE versus HEPZATO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLEOSTINE versus HEPZATO.
GLEOSTINE vs HEPZATO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
HEPZATO (melphalan) is a nitrogen mustard alkylating agent that crosslinks DNA strands, inhibiting DNA replication and transcription, leading to cell death.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
Melphalan 3 mg/kg ideal body weight via hepatic artery infusion over 15-30 minutes followed by hemofiltration, administered once per treatment cycle.
None Documented
None Documented
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
The terminal elimination half-life of melphalan is approximately 1.5 hours following intravenous administration. This short half-life necessitates regional delivery (hepatic arterial infusion) to achieve high local concentrations with limited systemic exposure.
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
HEPZATO (melphalan hydrochloride) for injection is renally eliminated; approximately 20-30% of the administered dose is excreted unchanged in the urine over 24 hours. The major metabolites are hydrolysis products, which are also excreted renally. Biliary/fecal elimination accounts for less than 10% of the dose.
Category C
Category C
Alkylating Agent
Alkylating Agent